← Back to Search

Alinity m HR HPV for Human Papillomavirus

N/A

Waitlist Available

Research Sponsored by Abbott Molecular

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to 12 weeks

Awards & highlights

No Placebo-Only Group

Summary

This trial tests two methods of collecting cervical cell samples in women undergoing routine screening. It aims to see which method is better at detecting abnormal cells and high-risk HPV, which could indicate a need for further examination.

Eligible Conditions

Human Papillomavirus

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to 12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Disease Progression greater than or equal to (cervical intraepithelial neoplasia) CIN3

Secondary study objectives

Disease progression greater than or equal to cervical intraepithelial neoplasia (CIN2)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Alinity m HR HPVExperimental Treatment1 Intervention

The Alinity m HR HPV IUO assay is a qualitative in vitro test that amplifies and detects HR HPV DNA in cervical cells collected in liquid media. The assay can differentiate between HPV 16, HPV 18, HPV 45 and non-HPV 16/18/45 genotypes \[(31/ 33/ 52/ 58) and (35/ 39/ 51/ 56/ 59/ 66/ 68)\].

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Alinity m HR HPV

2021

N/A

~14940

Do I qualify?Apply below to find out